Table 1 :
From: Treatment of invasive candidiasis with caspofungin in the intensive care unit
|  | End of IV study therapy | Confirmed relapse at 6–8 weeks post-therapy | All-cause mortality at 6–8 weeks post-therapy |
|---|---|---|---|
ICU patients | 59/97 (61%) [51%, 71%] | 10/59 (17%) [7%, 27%] | 41/97 (42%) [32%, 52%] |
CAS | 27/40 (68%) [53%, 82%] | 5/27 (19%) [4%, 33%] | 18/40 (45%) [29%, 61%] |
AmB | 32/57 (56%) [43%, 69%] | 5/32 (16%) [3%, 28%] | 23/57 (40%) [28%, 53%] |
Non-ICU patients | 92/127 (72%) [65%, 80%] | 5/92 (5%) [1%, 10%] | 30/127 (24%) [16%, 31%] |